

Donald P Mcdonnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5904162/publications.pdf>

Version: 2024-02-01

126
papers

12,897
citations

17405

63
h-index

24915

109
g-index

135
all docs

135
docs citations

135
times ranked

14460
citing authors

#	ARTICLE	IF	CITATIONS
1	The Estrogen Receptor β -Isoform (ER β) of the Human Estrogen Receptor Modulates ER α Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens ¹ . <i>Endocrinology</i> , 1999, 140, 5566-5578.	1.4	939
2	27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology. <i>Science</i> , 2013, 342, 1094-1098.	6.0	635
3	Connections and Regulation of the Human Estrogen Receptor. <i>Science</i> , 2002, 296, 1642-1644.	6.0	518
4	The Human Estrogen Receptor- β Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators. <i>Journal of Biological Chemistry</i> , 2001, 276, 35684-35692.	1.6	404
5	Peptide Antagonists of the Human Estrogen Receptor. <i>Science</i> , 1999, 285, 744-746.	6.0	352
6	Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β . <i>Molecular and Cellular Biology</i> , 1999, 19, 8226-8239.	1.1	349
7	Common Estrogen Receptor Polymorphism Augments Effects of Hormone Replacement Therapy on E-Selectin but Not C-Reactive Protein. <i>Circulation</i> , 2002, 105, 1879-1882.	1.6	314
8	Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 343-357.	3.4	273
9	The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. <i>Nature Communications</i> , 2017, 8, 864.	5.8	261
10	27-Hydroxycholesterol Is an Endogenous Selective Estrogen Receptor Modulator. <i>Molecular Endocrinology</i> , 2008, 22, 65-77.	3.7	255
11	Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. <i>Communications Biology</i> , 2018, 1, 100.	2.0	249
12	Allosteric Regulation of Estrogen Receptor Structure, Function, and Coactivator Recruitment by Different Estrogen Response Elements. <i>Molecular Endocrinology</i> , 2002, 16, 469-486.	3.7	230
13	Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism. <i>Molecular Cell</i> , 2005, 18, 413-424.	4.5	225
14	Comparative Analyses of Mechanistic Differences Among Antiestrogens ¹ . <i>Endocrinology</i> , 1999, 140, 5828-5840.	1.4	214
15	Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers. <i>Journal of Biological Chemistry</i> , 1995, 270, 22777-22782.	1.6	205
16	Modulation of Estrogen Receptor- β Transcriptional Activity by the Coactivator PGC-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 16302-16308.	1.6	193
17	The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens. <i>Molecular Cell</i> , 2009, 36, 405-416.	4.5	183
18	Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic. <i>Cancer Research</i> , 2008, 68, 7475-7483.	0.4	182

#	ARTICLE	IF	CITATIONS
19	Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1155-1168.	2.1	168
20	Systematic identification of signaling pathways with potential to confer anticancer drug resistance. <i>Science Signaling</i> , 2014, 7, ra121.	1.6	163
21	The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. <i>Current Opinion in Pharmacology</i> , 2010, 10, 620-628.	1.7	162
22	A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. <i>Cell Metabolism</i> , 2017, 26, 648-659.e8.	7.2	154
23	Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4883-4887.	2.9	147
24	Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 9659-9662.	7.2	146
25	Copper Signaling Axis as a Target for Prostate Cancer Therapeutics. <i>Cancer Research</i> , 2014, 74, 5819-5831.	0.4	143
26	Cholesterol and breast cancer pathophysiology. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 649-655.	3.1	141
27	Estrogen-Related Receptor β Is Critical for the Growth of Estrogen Receptor-Negative Breast Cancer. <i>Cancer Research</i> , 2008, 68, 8805-8812.	0.4	138
28	Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease. <i>Clinical Cancer Research</i> , 2013, 19, 2420-2431.	3.2	127
29	WNT11 Expression Is Induced by Estrogen-Related Receptor β and β -Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration. <i>Cancer Research</i> , 2010, 70, 9298-9308.	0.4	126
30	The Metabolic Regulator ERR β , a Downstream Target of HER2/IGF-1R, as a Therapeutic Target in Breast Cancer. <i>Cancer Cell</i> , 2011, 20, 500-510.	7.7	126
31	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5121-5130.	3.2	126
32	CaM Kinase Kinase β -Mediated Activation of the Growth Regulatory Kinase AMPK Is Required for Androgen-Dependent Migration of Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 528-537.	0.4	124
33	The turnover of estrogen receptor β by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. <i>Biochemical Pharmacology</i> , 2011, 82, 122-130.	2.0	118
34	ERR β -Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 323-335.	2.9	113
35	Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. <i>Nature Communications</i> , 2021, 12, 5103.	5.8	111
36	Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators. <i>Endocrine Reviews</i> , 2002, 23, 295-316.	7.1	111

#	ARTICLE	IF	CITATIONS
37	BRCA1 expression is not directly responsive to estrogen. <i>Oncogene</i> , 1997, 14, 115-121.	2.6	109
38	Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Down-regulators. <i>Cancer Research</i> , 2007, 67, 9549-9560.	0.4	107
39	Identification and Structure-Activity Relationship of Phenolic Acyl Hydrazones as Selective Agonists for the Estrogen-Related Orphan Nuclear Receptors ERR1 ² and ERR1 ³ . <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3107-3109.	2.9	105
40	Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degradar (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2837-2864.	2.9	103
41	Identification of a Negative Regulatory Surface within Estrogen Receptor β Provides Evidence in Support of a Role for Corepressors in Regulating Cellular Responses to Agonists and Antagonists. <i>Molecular Endocrinology</i> , 2002, 16, 1778-1792.	3.7	97
42	Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 7199-7204.	3.3	97
43	The Endogenous Selective Estrogen Receptor Modulator 27-Hydroxycholesterol Is a Negative Regulator of Bone Homeostasis. <i>Endocrinology</i> , 2010, 151, 3675-3685.	1.4	96
44	The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. <i>Bone</i> , 2013, 53, 42-50.	1.4	96
45	Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. <i>Nature Communications</i> , 2018, 9, 1677.	5.8	96
46	The Oxysterol, 27-Hydroxycholesterol, Links Cholesterol Metabolism to Bone Homeostasis Through Its Actions on the Estrogen and Liver X Receptors. <i>Endocrinology</i> , 2011, 152, 4691-4705.	1.4	92
47	Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor. <i>Molecular Endocrinology</i> , 1997, 11, 747-754.	3.7	90
48	Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology. <i>Journal of Biological Chemistry</i> , 1998, 273, 6679-6688.	1.6	90
49	Obesity, Cholesterol Metabolism, and Breast Cancer Pathogenesis. <i>Cancer Research</i> , 2014, 74, 4976-4982.	0.4	86
50	Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 114, 106-112.	1.2	83
51	CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 1662-1673.	0.4	83
52	The Signaling Pathways Project, an integrated \omicron omics knowledgebase for mammalian cellular signaling pathways. <i>Scientific Data</i> , 2019, 6, 252.	2.4	82
53	Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. <i>Endocrine-Related Cancer</i> , 2015, 22, 713-724.	1.6	81
54	Thyroid hormone receptor and ERR β coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function. <i>Science Signaling</i> , 2018, 11, .	1.6	80

#	ARTICLE	IF	CITATIONS
55	A Negative Coregulator for the Human ER. <i>Molecular Endocrinology</i> , 2002, 16, 459-468.	3.7	79
56	Androgen receptor cofactor interactions as targets for new drug discovery. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 225-228.	4.0	74
57	Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4069-78.	3.3	74
58	Development of an ER Action Indicator Mouse for the Study of Estrogens, Selective ER Modulators (SERMs), and Xenobiotics. <i>Endocrinology</i> , 2001, 142, 4721-4728.	1.4	72
59	Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 339-349.	1.6	72
60	CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. <i>Nature Communications</i> , 2019, 10, 2450.	5.8	72
61	Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes. <i>Molecular Endocrinology</i> , 2002, 16, 647-660.	3.7	71
62	Development of Peptide Antagonists That Target Estrogen Receptor β -Coactivator Interactions. <i>Molecular Endocrinology</i> , 2000, 14, 2010-2023.	3.7	69
63	Molecular Pathways: The Metabolic Regulator Estrogen-Related Receptor β as a Therapeutic Target in Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6089-6095.	3.2	69
64	Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators. <i>Molecular Endocrinology</i> , 2006, 20, 1201-1217.	3.7	66
65	Coactivation of Liver Receptor Homologue-1 by Peroxisome Proliferator-Activated Receptor β Coactivator-1 on Aromatase Promoter II and Its Inhibition by Activated Retinoid X Receptor Suggest a Novel Target for Breast-Specific Antiestrogen Therapy. <i>Cancer Research</i> , 2005, 65, 11762-11770.	0.4	65
66	Receptor-Selective Coactivators as Tools to Define the Biology of Specific Receptor-Coactivator Pairs. <i>Molecular Cell</i> , 2006, 24, 797-803.	4.5	65
67	Induction of Krüppel-Like Factor 5 Expression by Androgens Results in Increased CXCR4-Dependent Migration of Prostate Cancer Cells <i>in Vitro</i> . <i>Molecular Endocrinology</i> , 2009, 23, 1385-1396.	3.7	62
68	The molecular determinants of estrogen receptor pharmacology. <i>Maturitas</i> , 2004, 48, 7-12.	1.0	57
69	Research Resource: Transcriptional Profiling in a Cellular Model of Breast Cancer Reveals Functional and Mechanistic Differences Between Clinically Relevant SERM and Between SERM/Estrogen Complexes. <i>Molecular Endocrinology</i> , 2012, 26, 1235-1248.	3.7	55
70	MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 20381-20394.	0.8	52
71	Definition of the Molecular Basis for Estrogen Receptor-Related Receptor- β -Cofactor Interactions. <i>Molecular Endocrinology</i> , 2007, 21, 62-76.	3.7	51
72	PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. <i>Science Translational Medicine</i> , 2016, 8, 369ra175.	5.8	49

#	ARTICLE	IF	CITATIONS
73	Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. <i>American Journal of Cardiology</i> , 2002, 90, F35-F43.	0.7	48
74	Identification of Ligand-Selective Peptide Antagonists of the Mineralocorticoid Receptor Using Phage Display. <i>Molecular Endocrinology</i> , 2011, 25, 32-43.	3.7	46
75	MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. <i>Hormones and Cancer</i> , 2017, 8, 69-77.	4.9	45
76	Mining the Complexities of the Estrogen Signaling Pathways for Novel Therapeutics. <i>Endocrinology</i> , 2003, 144, 4237-4240.	1.4	43
77	Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12178-12183.	3.3	43
78	Fasting-Induced Hepatic Production of DHEA Is Regulated by PGC-1 α , ERR α , and HNF4 α . <i>Molecular Endocrinology</i> , 2009, 23, 1171-1182.	3.7	41
79	From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). <i>Steroids</i> , 2014, 90, 30-38.	0.8	41
80	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. <i>Cell Reports</i> , 2019, 29, 889-903.e10.	2.9	40
81	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 2326-2338.	3.9	40
82	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	40
83	HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. <i>Prostate</i> , 2019, 79, 414-424.	1.2	39
84	The Nuclear Receptor-Coactivator Interaction Surface as a Target for Peptide Antagonists of the Peroxisome Proliferator-Activated Receptors. <i>Molecular Endocrinology</i> , 2007, 21, 2361-2377.	3.7	38
85	27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 510-514.	4.0	38
86	Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 659-669.	1.9	38
87	Estrogen Receptor Signaling in the Immune System. <i>Endocrine Reviews</i> , 2023, 44, 117-141.	8.9	38
88	Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degradar for ER α Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2790-2818.	2.9	36
89	Delineation of a FOXA1/ER α /AGR2 Regulatory Loop That Is Dysregulated in Endocrine Therapy-Resistant Breast Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 1829-1839.	1.5	35
90	Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. <i>Cancer Research</i> , 2003, 63, 8029-36.	0.4	35

#	ARTICLE	IF	CITATIONS
91	Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM. <i>Annals of the New York Academy of Sciences</i> , 2001, 949, 16-35.	1.8	34
92	The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. <i>Clinical Cancer Research</i> , 2005, 11, 871s-7s.	3.2	33
93	Mechanisms of Progesterone Receptor Inhibition of Inflammatory Responses in Cellular Models of Breast Cancer. <i>Molecular Endocrinology</i> , 2010, 24, 2292-2302.	3.7	32
94	Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor- β degrader activity in antitumor efficacy. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 67-77.	1.1	30
95	Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 53, 487-495.	1.2	29
96	Inhibition of ER β Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. <i>Cell Reports</i> , 2019, 27, 3587-3601.e4.	2.9	29
97	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 748-759.	1.6	28
98	Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 266-277.	1.2	28
99	The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1395-1405.	1.9	26
100	The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. <i>Archives of Biochemistry and Biophysics</i> , 2007, 460, 206-212.	1.4	25
101	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. <i>Gynecologic Oncology</i> , 2019, 154, 199-206.	0.6	23
102	Development of an ER Action Indicator Mouse for the Study of Estrogens, Selective ER Modulators (SERMs), and Xenobiotics. , 0, .		23
103	Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. <i>Molecular Endocrinology</i> , 2015, 29, 1426-1439.	3.7	22
104	CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. <i>Molecular Cancer Research</i> , 2017, 15, 660-669.	1.5	22
105	Pregnancy and Smoothelin-like Protein 1 (SMTNL1) Deletion Promote the Switching of Skeletal Muscle to a Glycolytic Phenotype in Human and Mice. <i>Journal of Biological Chemistry</i> , 2015, 290, 17985-17998.	1.6	19
106	Next-Generation Endocrine Therapies for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1383-1388.	0.8	19
107	DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin. <i>Endocrinology</i> , 2017, 158, 3212-3234.	1.4	17
108	Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. <i>Oncotarget</i> , 2016, 7, 84030-84042.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. <i>Nature Chemical Biology</i> , 2016, 12, 795-801.	3.9	15
110	Application of Random Peptide Phage Display to the Study of Nuclear Hormone Receptors. <i>Methods in Enzymology</i> , 2003, 364, 118-142.	0.4	14
111	27-Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case-Cohort Study in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 59-66.	3.1	12
112	Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. <i>FASEB Journal</i> , 2006, 20, 2432-2434.	0.2	11
113	Creation of an active estrogen-responsive element by a single base change in the flanking sequence of a cellular oncogene: A possible mechanism for hormonal carcinogenesis?. <i>Molecular Carcinogenesis</i> , 1993, 7, 76-82.	1.3	10
114	4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 917-926.	1.4	10
115	Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. <i>Essays in Biochemistry</i> , 2021, 65, 985-1001.	2.1	10
116	Identification and Characterization of Novel Estrogen Receptor- β -Sparing Antiprogestins. , 0, .		7
117	Targeting mutant estrogen receptors. <i>ELife</i> , 2019, 8, .	2.8	6
118	Neomorphic ER β Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery. <i>Cancer Cell</i> , 2018, 33, 153-155.	7.7	4
119	Decoding the Inversion Symmetry Underlying Transcription Factor DNA-Binding Specificity and Functionality in the Genome. <i>IScience</i> , 2019, 15, 552-591.	1.9	2
120	A New Chemotype of Chemically Tractable Nonsteroidal Estrogens Based on a Thieno[2,3- <i>d</i>]pyrimidine Core. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1151-1158.	1.3	1
121	Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12651-12669.	2.9	0
122	SERMs (Selective Estrogen Receptor Modulators). , 2003, , 335-340.		0
123	Modulation of Aldehyde Dehydrogenase and Retinoid Signaling Induces the Expansion of Human Hematopoietic Stem Cells.. <i>Blood</i> , 2005, 106, 1713-1713.	0.6	0
124	The Retinoid X Receptor Regulates Human Hematopoietic Stem Cell Fate.. <i>Blood</i> , 2006, 108, 1324-1324.	0.6	0
125	MON-218 Inflammatory Role of Sex Steroids in Hidradenitis Suppurativa: An Androgenic Phenotype. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
126	Defining the molecular pharmacology of disease relevant estrogen receptor mutations for effective therapeutic targeting in breast cancer. <i>FASEB Journal</i> , 2019, 33, 815.4.	0.2	0